GSK Manufacturing Hits Another Snag With Lamictal Recall
This article was originally published in The Pink Sheet Daily
Executive Summary
Some Lamictal starter kits may contain an inappropriate dose of the anti-epileptic, which could lead to unsafe rapid titration. GSK estimates that 100,000 kits in the supply chain would be subject to the recall.